Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03648268 · ClinicalTrials.gov registry record · NA
Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia
A NA study of Schizophrenia and Schizoaffective Disorder, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT03648268: Completed NA study of Schizophrenia and Schizoaffective Disorder, sponsored by Beth Israel Deaconess Medical Center.
NCT03648268 is a NA study of Schizophrenia and Schizoaffective Disorder that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 47 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03648268, a NA study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to learn how transcranial magnetic stimulation (TMS) helps improve negative symptoms of schizophrenia. These 'negative symptoms' include anhedonia (the inability to enjoy things), low motivation, and decreased facial expression. TMS is a noninvasive way of stimulating the brain. TMS uses a magnetic field to cause changes in activity in the brain. The magnetic field is produced by a coil that is held next to the scalp. In this study we will be stimulating the brain to learn more about how TMS may improve these symptoms from schizophrenia.
Primary Outcome
We will evaluate the effect of sham vs active rTMS on The Positive and Negative Syndrome Scale for Schizophrenia (PANSS) Negative Symptom total score. This score is the sum of seven questions on the PANSS questionnaire (named N1-N7). Each question is scored from 1-7 for a total score per individual ranging from 7-49. On this scale higher numbers indicate great symptomology
Conditions Studied
Interventions
- DEVICE repetitive Transcranial Magnetic Stimulation (rTMS)
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2023-12-22 |
| Phase | NA |
What the finished NCT03648268 record still lists
NCT03648268 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (79% lower).
The record links to 3 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which repetitive Transcranial Magnetic Stimulation (rTMS) is the first listed.
NCT03648268 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03648268 about?
NCT03648268 is a clinical study titled "Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia". The main purpose of this study is to learn how transcranial magnetic stimulation (TMS) helps improve negative symptoms of schizophrenia. These 'negative symptoms' include anhedonia (the inability to enjoy things), low motivation, and decreased facial expression. TMS is a noninvasive way of stimulat...
What is the current status of trial NCT03648268?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2019-05-02. Estimated completion is 2023-12-22.
What conditions does trial NCT03648268 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder, Negative Type; Schizophrenic.
What interventions are being tested in trial NCT03648268?
The interventions under investigation include: repetitive Transcranial Magnetic Stimulation (rTMS) (DEVICE).
Who is sponsoring clinical trial NCT03648268?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03648268 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03648268's enrollment target sits among peer trials
47 223rd of 315 higher than 91 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 1)
RECRUITING · NA
-
Cerebellar Modulation of Cognition in Psychosis
RECRUITING · NA
-
TMS for Inhibition Enhancement in Schizophrenia
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI